- Business
- Zhejiang Hisun Pharmaceutical Co., Ltd. Zhejiang Hisun Pharmaceutical Co., Ltd. (600267.SS) is a China-based pharmaceutical company engaged in the research, development, production, and sale of innovative drugs, biological drugs, generic drugs, and high-end active pharmaceutical ingredients (APIs). The company offers a broad portfolio of products covering more than ten therapeutic areas, including anti-tumor drugs, anti-infection drugs, cardiovascular drugs, endocrine drugs, immunosuppression drugs, antidepressants, liver care treatments, orthopedics drugs, antiparasitic drugs, veterinary drugs, anti-viral drugs, anti-TB drugs, weight loss drugs, and animal healthcare products; it manufactures both APIs and finished dosage forms such as capsules, tablets, and injectables. Zhejiang Hisun Pharmaceutical Co., Ltd. operates manufacturing facilities in locations including Taizhou, Fuyang, and Nantong, exports APIs to approximately 70 countries worldwide with 80% of API revenue from overseas markets, and maintains a domestic sales network covering all of China with products prescribed in nearly 10,000 hospitals; founded in 1956 and headquartered in Taizhou, Zhejiang Province, China, it employs over 5,000 people and ranks among China's largest producers of antibiotics and anti-tumor drugs. In recent developments, the company signed a Memorandum of Understanding in December 2024 with Sijilmasa Ltd. and One Belt and One Road Group Limited to build pharmaceutical plants in Morocco and the UAE, aiming to expand in the Middle East and Africa; it completed the acquisition of the remaining 49% stake in Hanhui Pharmaceutical Co., Ltd. from Hillhouse, strengthening its control over key assets; and on November 10, 2025, announced plans to list a 100% stake in its wholly-owned subsidiary Provincial Pharmaceutical Company on the Taizhou Property Rights Exchange with a minimum price of RMB 4.3 billion. The company also received China veterinary drug approvals in November 2025 for nystatin ointment and toltrazuril products, and continues to invest in R&D with over 1,000 patents applied for and advanced facilities including a state-level technology center and post-doctoral research center.